We mine the human memory B-cell repertoire of Elite Responders

Our innovative technologies include a proprietary, clinically validated human-antibody discovery platform to identify therapeutically relevant antibodies from patients with elite response to their cancer following immunotherapy. The platform allows for the rapid screening of tens of thousands of antibodies made by the human immune system to identify immuno-modulatory antibodies to high value targets.

MD Anderson Cancer Center accelerates our discovery

In collaboration with MD Anderson Cancer Center (MDACC), we are using the platform to identify antibodies made by Elite Responders that modulate myeloid cells in the tumor microenvironment. MDACC not only provides access to blinded patient tissues and their respective physiologic, genotypic and clinical therapy data but also lends their oncology and translational medicine expertise.